|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Hereditary Neoplastic Syndrome | |||||
| Tuberous Sclerosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Neoplastic Syndromes, Hereditary | |||||
| Sclerosis | |||||
| Syndrome | |||||
| 3 | More general conditions related to this trial | ||||
| Congenital Abnormalities | |||||
| Disease | |||||
| Genetic Diseases, Inborn | |||||
| Hamartoma | |||||
| Heredodegenerative Disorders, Nervous System | |||||
| Malformations of Cortical Development | |||||
| Neoplasms | |||||
| Nervous System Diseases | |||||
| Nervous System Malformations | |||||
| Neurocutaneous Syndromes | |||||
| Neurodegenerative Diseases | |||||
| Pathologic Processes | |||||
| 4 | Sponsors listed in this trial | ||||
| National Heart, Lung, and Blood Institute (NHLBI) | |||||